David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.

Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.

Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.

Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.

Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.

Jason Efstathiou and Piet Ost discuss the data for and against this approach.

Alison Birtle describes adjuvant chemotherapy in bladder cancer.

Daniel Goldstein describes his work on this issue.

In this second part, Matt Galsky describes the OS signal data. We also look into the future.

Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.

Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.

Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.

FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.

Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.

Michael Lattanzi discusses treatment plans and research in the community.

Hans Hammers discusses trial design and patient selection in the adjuvant setting.

Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries

David McDermott discusses melanoma and renal data. We never get to bladder or lung.

Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer

Silke, Tom and Brian cover the bases.

Neeraj Agarwal addresses the issues raised at the meeting.

Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005